Character Biosciences is a precision medicine company focused on developing targeted therapies for polygenic diseases, with an emphasis on ophthalmology. The company employs a comprehensive patient data platform that combines genomic information with extensive clinical and imaging data. This integration helps in identifying genetic factors that contribute to disease progression, facilitating the development of novel therapeutics, and creating effective patient stratification strategies. Established in 2018, Character is actively working on clinical programs related to Dry Age-related Macular Degeneration (AMD) and is supported by a diverse interdisciplinary team. The company also collaborates with major investors in the healthcare and technology sectors, ensuring a commitment to advancing precision medicine through rigorous scientific research and innovative drug discovery.